Who Paid My Doc
Hrak Jalian
Procedural Dermatology Santa Monica, CA Medical Doctor
NPI 1023260346 CMS profile 876167
2020 Santa Monica Blvd Ste 570, Santa Monica, CA 90404
General payments
$159,783
Research payments
$80
Ownership & investment interest
$0
Research they led as principal investigator
$83,000
Through program year 2025, Hrak Jalian of Santa Monica, CA is reported in the CMS Open Payments database as having received $159,783 across 283 general payments and $80 in research payments paid to them. Separately, studies naming them as principal investigator received $83,000 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 93rd percentile of Procedural Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $21,092 | 33 | |
| 2024 | General | $30,356 | 40 | |
| 2023 | General | $67,249 | 54 | |
| 2022 | General | $24,169 | 45 | |
| 2022 | Research | $80 | 6 | |
| 2021 | General | $15,934 | 56 | |
| 2020 | General | $130 | 10 | |
| 2019 | General | $851 | 45 |
Beside peers
- Hrak Jalian
- Procedural Dermatology median
- Middle half of Procedural Dermatology
- National median
In program year 2025, general payments to Hrak Jalian were reported at $21,092. Among 381 Procedural Dermatology profiles paid that year, the median was $592 and the middle half received between $144 and $1,778.
Show as a table
| Year | Hrak Jalian | Procedural Dermatology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $851 | $454 | $152–$1,260 | $163 |
| 2020 | $130 | $243 | $90–$835 | $114 |
| 2021 | $15,934 | $337 | $102–$1,128 | $132 |
| 2022 | $24,169 | $443 | $119–$1,654 | $149 |
| 2023 | $67,249 | $583 | $137–$1,838 | $160 |
| 2024 | $30,356 | $611 | $132–$1,835 | $164 |
| 2025 | $21,092 | $592 | $144–$1,778 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
289 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Procedural Dermatology in California
Sam Khalifian
Procedural Dermatology · La Mesa, CA
Sabrina Fabi
Procedural Dermatology · San Diego, CA
Natasha Mesinkovska
Procedural Dermatology · Mission Viejo, CA
Jeanette Black
Procedural Dermatology · Los Angeles, CA
Mitchel Goldman
Procedural Dermatology · San Diego, CA
Rebecca Fitzgerald
Procedural Dermatology · Los Angeles, CA
Related records
Procedural Dermatology in California
Practitioners in the same specialty and state, ranked by reported value.
All Procedural Dermatology
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.